Previous 10 | Next 10 |
home / stock / wxibf / wxibf news
2024-02-01 03:00:00 ET Summary Beijing is rolling out a host of measures to boost economic growth and support sagging stock markets. The policies helped Hong Kong’s Hang Seng jump 4.2% last week, breaking a January losing streak. Under a new policy, market valuation will be...
2024-01-19 04:46:37 ET Summary WuXi Biologics' Hong Kong-listed shares witnessed a strong rebound in recent days due to better-than-expected new project disclosures and continued share buybacks. But the stock's valuations are unappealing and the company's top line growth outl...
2023-12-10 02:15:00 ET Summary Shanghai Abbisko Therapeutics has sold greater China commercialization rights for pimicotinib to Germany's Merck in a $605 million deal. Xtalpi, a China-US AI drug discovery company, has filed for a Hong Kong IPO after raising $780 million in venture...
2023-12-06 02:05:56 ET Summary WuXi Biologics is a contract-based drug developer in China, but recent share price performance has lagged. The company is expecting a major miss in revenues for FY 2023 due mostly to over-optimism, causing a 30% decline in share price. Despite th...
2023-11-29 17:57:54 ET Summary Ajinomoto is diversifying its revenue segments, particularly in the biopharma and semiconductor industries, for organic growth opportunities. The company has a leading market position, high R&D investment, and above-peer margins in the consumer s...
2023-11-26 02:40:00 ET Summary BeiGene acquires global rights to a preclinical CDK2 inhibitor from Ensem Therapeutics in a $1.3 billion agreement. Shanghai Usynova Biopharma out-licenses global rights for its KRASG12D inhibitor to AstraZeneca in a deal worth up to $419 million. ...
2023-10-08 09:40:00 ET Summary Jiangsu QYuns Therapeutics has filed for a Hong Kong IPO to underwrite development of its portfolio of clinical-stage biologic antibody drugs for autoimmune and allergic diseases. Taiwan’s PharmaEssentia has acquired a myeloid immune checkpoin...
2023-09-08 00:03:09 ET Summary The recent IRA list of 10 drug publications is not expected to have a significant impact on big pharma stocks in the near term. The legal challenges by big pharma companies against the IRA may derail the implementation of the drug pricing reforms. ...
2023-07-19 05:32:00 ET Summary The drug outsourcing services company is spinning off its WuXi XDC unit, seizing on investor enthusiasm for a new generation of highly targeted ADC drugs. WuXi XDC has filed for a Hong Kong IPO, calling itself the world’s second largest provid...
2023-06-14 06:28:00 ET Summary We’ve seen signs of improvement that are positive for the Chinese internet services sector, but that space also continues to be a place of extreme competitive aggression. As a result of the creation of economic zones, increased availability of...
News, Short Squeeze, Breakout and More Instantly...
Wuxi Biologics Cayman Inc Company Name:
WXIBF Stock Symbol:
OTCMKTS Market:
The pharmaceutical market reached a total value of US$1.27 trillion in 2020, according to data from Statista , up significantly from US$887 billion in 2010. By 2025, that value is expected to increase even further to an estimated US$1.6 billion. Experienced and novice invest...
Adlai Nortye Raises $100 Million in Series D Financing, Co-led by SDIC Fund Management and Tigermed, participated by Legend Star, WuXi Biologics Healthcare Ventures NEW JERSEY and HANGZHOU, CHINA, July 15, 2021 - (ACN Newswire) - Adlai Nortye Ltd. (hereinafter referred to as "...